On September 11, 2024, Biomissile Pharmaceuticals was honored with the first-place award at 2024 CHINABIO® Partnering Forum’s “Startup Spotlight Pitch Competition” and a cash prize of RMB 500,000 by the forum sponsor. The company's presentation, titled "Overcoming ADC resistance: Next generation NK engagers (UDAB-MTM)” was delivered by Dr. Chao Tu, Co-founder, President & CEO of Biomissile. His compelling narrative and innovative vision clearly struck a chord with both the audience and the esteemed panel of judges, illustrating the company's groundbreaking work in the field of cancer treatment.
About CHINABIO®’s “Startup Spotlight Pitch Competition”
“The Startup Spotlight Pitch Competition” is a highlight of the CHINABIO® Partnering Forum, showcasing some of the most innovative startup biotech companies that are shaping the future of healthcare. This live competition offers a selected group of startups the invaluable opportunity to present their groundbreaking ideas to a panel of industry experts and an audience of their peers. The winner is announced at the conclusion of the session, marking a pivotal moment in the startup's journey.
About Biomissile
Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-MTM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stages (in Phase I & II) and the third one is in IND filing stage.
Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.
Link to the news in Chinese:
https://mp.weixin.qq.com/s/SZ9TQvdfCW5Or-8NYq-u-w
BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com